You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

Details for Patent: 11,219,621

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,219,621 protect, and when does it expire?

Patent 11,219,621 protects XOLREMDI and is included in one NDA.

This patent has thirty-four patent family members in eleven countries.

Summary for Patent: 11,219,621

Title:	Methods for treating immunodeficiency disease
Abstract:	The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.
Inventor(s):	Arbeit Robert D., Ragan Paula Marie
Assignee:	X4 Pharmaceuticals, Inc.
Application Number:	US16804863
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 11,219,621

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,219,621

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3008272	⤷ Sign Up
Canada	3008279	⤷ Sign Up
Canada	3009176	⤷ Sign Up
Canada	3010617	⤷ Sign Up
China	108883091	⤷ Sign Up
China	108883132	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.